Last reviewed · How we verify
NCT06782139: ENVY
Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity
Phase 4 trial testing Enavogliflozin in Obesity and Type 2 Diabetes in 30 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Korea University Anam Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 20 January 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Enavogliflozin — full drug profile →
- Placebo
Conditions studied
- Obesity and Type 2 Diabetes — all drugs for Obesity and Type 2 Diabetes →
Sponsor
Korea University Anam Hospital
Who can join
Adults 20 to 79, any sex, with Obesity and Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Epicardial adipose tissue in coronary microvascular disease.
Gašpárková V, Tran BT, Ošťádal P, Lambert L, et al · · 2026 · PMID 41694543 · DOI 10.1016/j.ahjo.2026.100734
Verify or expand the search:
- PubMed search for NCT06782139
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Enavogliflozin
Trials testing the same drug.
- NCT06528262 — Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation · Phase 4 · not yet recruiting
- NCT06642623 — A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients · Phase 4 · recruiting
- NCT05926414 — To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus · active not recruiting
Other recruiting trials for Obesity and Type 2 Diabetes
Currently open trials in the same condition.
- NCT06800794 — Investigating Metabolic and Psychological Adaptations in a Clinical Trial · NA · active not recruiting
- NCT07055516 — Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus · Phase 2 · active not recruiting
- NCT06890169 — OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities · NA · recruiting
- NCT06943001 — Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents · NA · recruiting
- NCT06830096 — Role of KATP Channel Loss in Type 2 Diabetes · NA · recruiting
Other Korea University Anam Hospital trials
Trials by the same sponsor.
- NCT07510932 — Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients · Phase 2 · not yet recruiting
- NCT07280780 — CGM-Based Glycemic Analysis After ESI · not yet recruiting
- NCT07189000 — Patient-centered REhabilitation Program to Advance REcovery · NA · not yet recruiting
- NCT07246148 — NOn-inVAsive Blood Pressure Monitoring in Intracranial Aneurysm Embolization · NA · recruiting
- NCT07376980 — The SMART Trial: Modified Single-Stapled Anastomosis in Laparoscopic or Robotic Low Anterior Resection for Rectal Cancer · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06782139 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Korea University Anam Hospital
- Last refreshed: 2 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06782139.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing